Frontiers Case report: Short-term eculizumab use in atypical HUS

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era

PDF) Anti-factor H antibody and its role in atypical hemolytic uremic syndrome

PDF) Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

PDF] Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

PDF) First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing

Frontiers Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis